News By: Gary Cramer

Clinical research has never been more digital, yet for research sites, the cumulative effect of the abundance of digital technologies now available can create a paradox: systems designed to improve efficiency may also introduce substantial administrative burden. This article examines technology fragmentation from a research site perspective and argues that the primary challenge is not digitalization itself, but the lack of integration and standardization across the clinical research ecosystem.

The title for this message, inspired by Marvel Comic’s multi-billion-dollar Avengers movie franchise, is a call to action from ACRP's new Chief Executive Officer. He writes that, like the superhero members of The Avengers, we each bring different capabilities, funds of knowledge, and experiences to the table…and yes, we can occasionally drive each other crazy. We can be successful individually in our own right, but when the stakes are high enough, we assemble. And the stakes are high enough.

Clinical research sites are responsible for turning clinical trial protocols into real-world execution, yet many capable and experienced sites remain underutilized. Despite strong investigator experience and operational infrastructure, sites often encounter barriers related to visibility, feasibility alignment, and fragmented communication across the clinical research ecosystem. This article examines the structural and operational factors that limit site participation in clinical trials. It outlines common breakdowns in feasibility and site selection processes, explores the increasing operational pressures facing site teams, and highlights practical strategies to improve site readiness and positioning.

When a clinical trial site receives a Clinical Trial Agreement or Master Services Agreement from a sponsor, most of the negotiating energy goes to the budget, the payment schedule, and the operational terms. The insurance and indemnification sections tend to get a quick read and a signature. This article explains why those sections deserve more attention, walks through the provisions sites will most commonly encounter, and offers a set of practical questions site leaders can raise internally or with their legal counsel and insurance advisors before an agreement is executed.

For years, the conversation about accelerating drug development has focused on scientific discovery: better target identification, faster molecule design, stronger predictive models, and, more recently, the growing role of artificial intelligence (AI). AI investment is now beginning to change the front end of the pipeline. More candidates can now be identified, prioritized, and advanced with unprecedented speed in the preclinical space. But that progress has exposed a different constraint: how to evaluate these promising therapies as they transition into humans at a pace the current clinical development system can sustain.